This trial is evaluating whether Levetiracetam will improve 1 primary outcome and 4 secondary outcomes in patients with Alzheimer Disease. Measurement will happen over the course of Assessed at enrollment, week 7, week 15, week 27, and month 12.
This trial requires 65 total participants across 1 different treatment group
This trial involves a single treatment. Levetiracetam is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Clinically useful criteria for the diagnosis of AD exist, but clinicians frequently miss or incorrectly consider many previously described signs. In this sample, a positive association with the occurrence of major depressive disorder underscored the need for further investigation concerning the possibility of depression-related neurodegeneration." - Anonymous Online Contributor
"There is emerging evidence that the amyloid hypothesis is not wholly correct. This raises the possibility that, given we understand the biochemical pathways that are responsible for the spread of the amyloid plaque, we could develop treatments that target these pathways and thus treat AD appropriately. The possibility of halting AD in the prodromal stage raises the prospect of early diagnosis, treatment and possibly a cure for AD." - Anonymous Online Contributor
"About 1.2 million people get AD during their lifetime. question: Does family history of Alzheimer disease affect age at onset in familial AD? answer: Findings from a recent study support the role of APOE4 allele in early onset for familial AD." - Anonymous Online Contributor
"Identifying environmental factors that are associated with increased risk of developing Alzheimer Disease in later life is a key step towards understanding the precise mechanisms of the disease. Further, as an understanding of the causes in earlier life may also lead to new therapies for late-onset Alzheimer's." - Anonymous Online Contributor
"AD is a progressive, incurable brain disorder leading to cognitive and functional decline and, later, death. It is estimated that 8 million people are diagnosed with AD worldwide, and that 3.8 million died of AD in 2017. The disease is characterized by extracellular plaques and intracellular neurofibrillary tangles. Both factors are composed of beta-amyloid (Aβ) and Tau proteins. The two forms are deposited in the brain and spinal cord and trigger inflammatory and neurotoxic processes." - Anonymous Online Contributor
"Treatments of moderate efficacy can also be helpful to a majority of people with moderate to severe Alzheimer's and can help to keep people with this disease as independent and functional as possible as long as possible. Common treatments for AD are acetylcholinesterase inhibitors, memantine, and rasagiline for mild to moderate AD; donepezil and galantamine for moderate AD; and the Alzheimer's disease medication, galantamine, for moderate to severe AD." - Anonymous Online Contributor
"Levitiracetam treatment improves cognitive function. When patients already enrolled in a clinical trial receive a placebo in an additional treatment-phase, the placebo group has a higher cognitive performance than a placebo group already included into a clinical trial." - Anonymous Online Contributor
"The ADG family can be useful as a prospective cohort and model to investigate the genetic susceptibility to AD. However, the results obtained so far do not support the hypothesis of a substantial genetic contribution to familial AD and the role of modifier genes. Further studies, however, would be of great value to validate the existence of modifier genes for AD and other common diseases." - Anonymous Online Contributor
"Levetiracetam was typically used in combination with other treatments in this analysis, although there was a clear indication for the treatment of a patient's epilepsy. Levetiracetam was used to treat patients with both AD and epilepsy who had either had a prior history of seizure disorder or, as in this analysis, a history of epilepsy prior to onset of their AD." - Anonymous Online Contributor
"Levetiracetam is efficacious for the treatment of TIA but has a limited number of common side effects such as fatigue, dizziness, somnolence (drowsiness), headache, and tremor. Because of the incidence, degree, and duration, clinicians should be aware of these common side effects from levetiracetam and use it judiciously." - Anonymous Online Contributor
"Currently there is no information on the adverse effects of LEV, and the existing data are limited given their small sample size. More, larger and longer-term studies are needed." - Anonymous Online Contributor
"Although data are limited, levetiracetam seems to have a role as a monotherapy for dementia related to AD. Further trials are warranted to show its true role." - Anonymous Online Contributor